StockNews.AI
SEER
StockNews.AI
187 days

Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

1. Seer, Inc. plans to announce Q4 and full-year 2024 financial results on Feb 27. 2. A conference call will follow the earnings report at 1:30 PM PT. 3. Seer's Proteograph Product Suite enables rapid proteomic analysis using engineered nanoparticles. 4. The platform is designed for research use and simplifies laboratory integration. 5. Seer offers a decentralized solution that can be adopted by various labs.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive earnings reports often lead to stock price increases; investor anticipation could drive demand.

How important is it?

Upcoming earnings can greatly influence investor sentiment and stock performance.

Why Short Term?

Immediate effects expected post-earnings announcement, followed by potential long-term impact.

Related Companies

SEERNASDAQLIFE
February 13, 2025 16:15 ET  | Source: Seer, Inc. REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio. Media Contact:Patrick Schmidtpr@seer.bio  Investor Contact:Carrie Mendivilinvestor@seer.bio 

Related News